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on GCF MMP-8 and TIMP-1 levels in gingivitis: a
randomized placebo-controlled study
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Background: The aim of the present study was to evaluate the effect of adjunctive chlorhexidine (CHX) mouthrinse
on gingival crevicular fluid (GCF) MMP-8 and TIMP-1 levels in plaque-associated gingivitis.
Methods: A total of 50 gingivitis patients were included in the present study. In addition to daily plaque control,
CHX group rinsed with CHX, while placebo group rinsed with placebo mouthrinse for 4 weeks. GCF samples were
collected, and clinical parameters including plaque index, papillary bleeding index, calculus index and pocket depth
were recorded at baseline and 4 weeks. GCF MMP-8 and TIMP-1 levels were determined by immunofluorometric
assay (IFMA) and enzyme-linked immunosorbent assay (ELISA), respectively.
Results: In both groups, GCF MMP-8 levels of anterior and posterior sites at four weeks were not different from
baseline (p > 0.05). There were no significant differences in GCF MMP-8 levels between the study groups at four
weeks (p > 0.05). GCF TIMP-1 levels of anterior and posterior sites at four weeks were higher compared to baseline
in both groups (p < 0.05). There was no significant difference in GCF TIMP level between the study groups at four
weeks (p > 0.05).
Conclusions: CHX usage had no significant effects on the GCF MMP-8 and TIMP-1 levels in plaque-associate
gingivitis. However, daily plaque control resulted in the increase of GCF TIMP-1 levels regardless of CHX usage.
Keywords: Chlorhexidine, Gingivitis, Gingival crevicular fluid, MMP-8, TIMP-1Background
Dental plaque is the major etiological factor associated
with the development of gingivitis [1]. Mostly, efficient
mechanical plaque control would be enough for the
resolution of the gingival inflammation. Antimicrobial
mouthrinses as adjuncts to daily plaque control is more
beneficial than only brushing when individuals are un-
able to consistently maintain adequate levels of plaque
control using mechanical methods alone [2,3]. Chlor-
hexidine (CHX) mouthrinse as antimicrobial agent is
considered as the gold standard in preventing the dental
plaque formation and gingival inflammation due to its
both antiplaque and antigingivitis effects [4-8].* Correspondence: oya_t@yahoo.com
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unless otherwise stated.Microorganisms of dental plaque stimulate host cells
to express their matrix metalloproteinases (MMPs),
which is one of the mechanisms leading to periodontal
tissue destruction [9]. MMP-8 is expressed by many
types of cells [9,10] and known to be the main host cell-
derived collagenase that contributes significantly to tis-
sue destruction and remodeling events in inflammatory
periodontal diseases [11-14]. Significant decreases in
gingival crevicular fluid (GCF) MMP-8 levels following
periodontal treatment including scaling and root plan-
ning have been reported [15]. However, there are limited
data related to the MMP-8 levels in gingivitis patients
[16-18]. Emingil et al. [17] demonstrated GCF MMP-8
total amount to be significantly higher in gingivitis pa-
tients compared to healthy controls. Atilla et al. [16]
found no significant difference in GCF MMP-8 levels be-
tween gingivitis and control subjects. Recently, the persist-
ence of MMP-8 at physiologic levels after treatment hasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the inflammatory process and the onset of the reparative
phase [19].
MMP activity is regulated by changes in the balance
between the expression and synthesis of MMPs and tis-
sue inhibitors of matrix metalloproteinases (TIMPs) [9].
TIMP-1 was demonstrated to be the major inhibitor of
MMPs in gingival tissues of patients with periodontal
disease [20-22]. The balance between MMPs and TIMPs
plays an essential role in maintaining the healthy con-
dition of periodontal tissues, and disturbed balance may
cause collagen breakdown and periodontal tissue destruc-
tion. It has been demonstrated that periodontal treatment
increased TIMP-1 expression and decreased the ratios of
MMPs/TIMP-1 in chronic periodontitis [23,24]. However,
previous studies have demonstrated controversial results
about TIMP-1 levels in periodontal disease. Both in-
creased and decreased TIMP-1 levels were reported
in GCF and gingival tissues of patients with periodontitis
[20-22,25-30].
We have previously showed CHX mouthrinse had lim-
ited beneficial effects on clinical periodontal parameters
but was not effective on GCF cytokine levels in gingivitis
[31]. It has been stated that CHX mouthrinses is very
efficient agent in reducing and/or preventing dental
plaque [32-34] and had an additional effect on the degree
of inflammation in oral cavity [3,6,32,34,35]. CHX can
inhibit MMPs and prevent oxidative activation of MMPs
and oxidative inactivation of α1-antitrypsin [36-38]. TIMP-
1 can also be inactivated by reactive oxygen species
[9]. Therefore, we hypothesized that the reduction of
dental plaque by CHX mouthrinse might affect the
GCF MMP-8 and TIMP-1 levels, which is known to
act as crucial mediators in inflammatory process of
periodontal diseases. To the best of our knowledge,
there is no study investigating the efficacy of CHX
mouthrinse in addition to daily plaque control on GCF
MMP-8 and TIMP-1 levels in the presence of plaque-
associated gingivitis. Therefore, the present study aimed
to determine the effect of adjunctive chlorhexidine mou-




A total of 50 gingivitis patients who were diagnosed ac-
cording to AAP consensus report [39] were included in
the present study. All consecutive subjects were re-
cruited from the Ege University, School of Dentistry,
Department of Periodontology over a period of 1 year
between 2006 and 2007. The study protocol was ap-
proved by the ethics committee of the Ege University
School of Medicine. Prior to participation, the purpose
and procedures were fully explained to all patients andall participants gave written informed consent in accord-
ance with Helsinki declaration. The study was designed,
conducted, analysed and reported according to guide-
lines for Good Clinical Practice.
Medical and dental histories were taken at pre-
screening visit. Inclusion criteria were: 18–45 years of
age, male or female patients with gingivitis associated
with dental plaque, clinical attachment level <3 mm, a
minimum of 20 teeth (teeth that have gross caries, were
fully crowned or extensively restored, orthodontic
banded, abutments, or third molars were not included in
the tooth count). Exclusion criteria were as follows: use
of tobacco products, history or current manifestation of
systemic disease that could impair immune response
such as diabetes mellitus, immunological disorders, he-
patitis and HIV infections, use of antibiotic or anti-
inflammatory or immunosuppressive drugs during 3
months period prior to the start of the trial, periodontal
therapy during the last 3 months, pregnancy or lactation
and oral contraceptives usage.
Study design
This clinical trial was a randomized, double-blind,
placebo-controlled, parallel-group study of four week
duration. The clinical trial was organized into 4 stages
including pre-screening, screening, baseline, and evalu-
ation. Each volunteer was subjected to a pre-screening
examination to assess the overall status of his/her denti-
tion. During the pre-screening visit, clinical and radio-
graphic evaluations were assessed for suitability to be
included in the study. A single examiner determined as-
sessment of patient eligibility for the study and enrol-
ment of patients into trial. Patients eligible for the study
returned to our clinic at screening visit in order to rec-
ord clinical parameters 2 days after pre-screening. A sin-
gle experienced examiner assessed the periodontal status
of each patient. The same examiner recorded all clinical
measurements over the course of the study that was un-
aware of the type of mouthrinse (CHX or placebo) pro-
vided to the patient. After being selected for the study,
the subjects who were unaware of the type of moun-
trinses were randomized either to CHX or to placebo
groups. The placebo mouthrinse was composed of CHX
mouthrinse ingredients except that it lacked the active
ingredients (chlorhexidine digluconate). Both CHX and
placebo bottles were similar in appearance.
At the baseline stage of the study the GCF samples
were collected. Following completion of the GCF sam-
pling, patients were randomly assigned to CHX or pla-
cebo groups by taking into account the gender, age and
the extent of the gingivitis by an independent periodon-
tist who kept the allocation information confident until
the data collection and biochemical analysis were com-
pleted. The extent of gingivitis was assessed according to
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the bleeding. Only the patients who have at least 30% of
the papillae with papillary bleeding index (PBI) 2 or 3
were included in the present study. The subjects were
given a fluoride containing dentifrice (Ipana®, P&G
GmbH, Germany) and toothbrush (Oral B indicator®,
P&G, Ireland) for use during the study period. All of the
patients received tooth brushing instructions of Modi-
fied Bass technique and brushed their teeth twice a day
with toothbrush and toothpaste given for four weeks.
Thirty minutes after toothbrushing, CHX group rinsed
with 10 ml of 0.2% CHX mouthrinse twice a day (once
in the morning and once in the evening before sleeping)
for 1 min. Thirty minutes after toothbrushing, placebo
group rinsed with 10 ml of placebo mouthrinse twice a
day (once in the morning and once in the evening before
sleeping) for 1 min. They also had to avoid rinsing after-
wards with water, as well as eating or drinking within
30 min. following the use of the mouthrinse. All patients
came to control visits once per week and returned their
mouthrinse bottles to the study supervisor. The side ef-
fects of the mouthrinses were reviewed every week dur-
ing the study period. If any painful side effect such as
mucosal ulcerations was observed, utilization of mou-
thrinses was broken and the patient was excluded from
the study. At the end of the 4 weeks period, GCF sam-
ples were taken and clinical recordings were repeated.
Clinical assessment
Clinical periodontal parameters including plaque index
(PI) [40], PBI [41], which were primary outcomes of the
present study, calculus index (CI) [42] and probing
pocket depth (PPD) were recorded at six sites of each
tooth. All measurements were performed by a single blin-
ded and calibrated examiner using a manual Williams
periodontal probe (Hu-Friedy, Chicago, IL). The intra-
examiner reliability was high as was revealed by intraclass
correlation coefficient 0.87 for PPD measurements and
0.85 for PI measurements.
GCF sampling
GCF samples were taken from mesiobuccal aspects of a
single rooted tooth (except premolars) and a multi-
rooted tooth in each subject. Prior to GCF sampling, the
supragingival plaque was removed from the interproxi-
mal surfaces with a sterile curette; these surfaces were
dried gently by an air syringe and were isolated by cot-
ton rolls. GCF was sampled with filter paper (Periopaper,
ProFlow, Inc., Amityville, NY). Paper strips were care-
fully inserted 1 mm into the crevice and left there for
30 seconds [43]. Care was taken to avoid mechanical in-
jury. Strips contaminated with blood were discarded
[44]. The absorbed GCF volume of each strip was deter-
mined by an electronic device (Periotron 8000, ProFlow,Inc., Amityville, NY) and placed into a sterile polypro-
pylene tube and kept at -80C until being analysed. The
readings from the Periotron 8000 were converted to an
actual volume (μl) by reference to the standard curve.
Immunofluorometric assay (IFMA) for MMP-8 and enzyme
linked immunosorbent assay (ELISA) for TIMP-1
The secondary outcomes of the present study were the
changes of the GCF MMP-8 and TIMP-1 levels. The
amounts of GCF MMP-8 were assayed by time-resolved
IFMA (Medix Biochemica, Kauniainen, Finland) [45].
IFMA utilizes two monoclonal anti-MMP-8 antibodies
and exerts higher accuracy. The antibody identifies the
neutrophil- and fibroblast-type MMP-8 isoforms and
particularly their active forms in IFMA technique. GCF
TIMP-1 was assayed by commercially available ELISA
kit (Amersham Biotrak, GE Healthcare, Buckingham-
shire, UK). Prior to the quantitation of MMP-8 and
TIMP-1, GCF samples were eluted from each strip into
75 μl of 50 mM Tris–HCl-buffer, pH 7.8, containing
0.2 M NaCl and 1 mM CaCl2 for 2 h at 22°C on a
shaker. The minimum detection limits of MMP-8 and
TIMP-1 were 0.08 ng/ml and 1.25 ng/ml, respectively.
All samples were assayed in duplicate. The amounts of
MMP-8 and TIMP-1 in each sample were calculated
based on the dilutions.
Statistical analysis
The power calculation analysis revealed that the re-
quired sample size was minimum 15 subjects for each
study group. Sample size of the present study was calcu-
lated to detect a 0.5 difference in PI and PBI scores at
the 0.05 probability level with a power of 80%. Decision
about whether to use parametric or non-parametric
tests were made based on the results of Kolmogorow-
Smirnow test for normal distribution.
Intragroup comparisons of the GCF MMP-8 and
TIMP-1 levels and the clinical parameters of the study
sites between baseline and four weeks were tested by
Wilcoxon signed rank test to analyze the significance of
changes over time. The Mann–Whitney test was used to
determine significant differences in GCF MMP-8 and
TIMP-1 levels and the clinical parameters of the study
sites between the CHX and placebo groups.
Results
Patient disposition and demographics
At the pre-screening stage of the present study, two
hundred and fifteen patients were examined. Ninety-two
patients did not fulfill the inclusion criteria and 36 pa-
tients did not accept to attend the study. Finally, a total
of 87 gingivitis patients who fulfilled all inclusion cri-
teria were included into the study. Random assignment
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in the placebo group.
Thirty-seven patients were excluded from the study
during clinical trial because of the following reasons:
seven patients in CHX group and nine patients in pla-
cebo group who did not use the mouthrinse regularly;
three patients in CHX group and three patients in pla-
cebo group who discontinued the study; seven patients
in CHX group and four patients in placebo group who
received antibiotics during the experimental period;
three from CHX and one from placebo group who had
mucosal ulcerations. Finally, a total of 50 patients, 25
from the CHX group and 25 from the placebo group,
completed the 4 weeks clinical trial (Figure 1). Intent to
treat analysis was not performed as data from non-
compliant patients had only baseline data. Statistical
analysis was performed on data from 50 patients who
completed the trial. There were no differences between
CHX and placebo groups in the age, gender, and the
distribution of the extent of gingivitis at the baseline
(Table 1).
Clinical periodontal parameters of whole mouth
The details of clinical findings of whole mouth were re-
ported previously [31]. Briefly, both treatment strategies
resulted in similar statistically and clinically significant
improvements on the basis of whole mouth PBI, PI, and
PPD values at 4 weeks when compared with baseline
levels. However, CHX group showed lower PI values
than the placebo group at 4 weeks (p < 0.05) and the re-
ductions in the PI from baseline were significantly greater
in the CHX group (p < 0.05).
Clinical periodontal parameters of sampling sites
There were no significant differences in clinical peri-
odontal parameters and GCF values of both anterior and
posterior sampling sites between CHX and placebo
groups at baseline (p > 0.05). No statistically significant
difference was detected in periodontal parameters in-
cluding PPD, PBI, PI, CI and GCF values of anterior
sampling sites at 4 weeks compared to baseline in both
groups (p > 0.05) (Table 2). There was no statistically sig-
nificant difference in PPD, PBI and CI and GCF values
of posterior sampling sites of patients in both CHX and
placebo groups at 4 weeks compared to baseline (p >
0.05) (Table 3). Posterior sampling sites of CHX group
had significantly lower PI values compared to those sites
of placebo group at four weeks (p < 0.05) (Table 3).
Laboratory findings of sampling sites
Figure 2A and B show GCF MMP-8 total amounts of
anterior and posterior sites in both study groups at base-
line and four weeks. At baseline, there were no signifi-
cant differences in GCF MMP-8 total amounts of bothanterior and posterior sampling sites between CHX and
placebo groups (p > 0.05). In both CHX and placebo
groups, GCF MMP-8 total amounts of anterior and pos-
terior sites at four weeks were not significantly different
from baseline levels (p > 0.05). There were no significant
differences in GCF MMP-8 total amounts between the
study groups at four weeks (p > 0.05). GCF TIMP-1 total
amounts of anterior and posterior sites in both study
groups at baseline and four weeks are shown in Figure 3.
There were no significant differences in GCF TIMP-1
total amounts of both anterior and posterior sampling
sites between CHX and placebo groups at baseline (p >
0.05). GCF TIMP-1 total amounts of anterior and pos-
terior sites at four weeks were higher compared to base-
line in both CHX and placebo groups (p < 0.05). There
was no significant difference in GCF TIMP-1 total
amount between the study groups at four weeks (p >
0.05) (Figure 3). When the data was calculated as con-
centration, similar pattern was obtained for GCF MMP-
8 and TIMP-1 levels in both intergroup and intragroup
comparisons (data not shown).
Adverse effects and treatment compliance
Adverse event information such as pain, sensitivity,
change in the taste perception, mucosal ulcerations, dis-
colorations were recorded. Of the 25 subjects who
rinsed their mouth with CHX mouthrinse, 5 of them ex-
perienced taste disturbances and 14 patient showed dis-
colouration of teeth and/or tongue. Three subjects had
mucosal ulcerations in CHX group.
Discussion
In this short term, randomized, placebo controlled clin-
ical study, which is a continuation of previously pub-
lished studies [31,34], the effectiveness of CHX as an
adjunct to daily plaque control on both clinical and GCF
MMP-8 and TIMP-1 levels were evaluated in gingivitis
patients. On the basis of the present findings, it can be
concluded that adjunctive CHX provides no additional
benefit over daily plaque control on GCF MMP-8 levels
and periodontal parameters except on plaque accumula-
tion at posterior sites in gingivitis patients. GCF TIMP-1
levels were increased similarly in CHX and placebo
groups at 4 weeks when compared to baseline. In other
words, daily plaque control procedures showed no sig-
nificant effects on the GCF MMP-8 levels in plaque-
associated gingivitis but increased GCF TIMP-1 levels
regardless of CHX usage.
Our previous study showed that CHX mouthrinse pro-
vided an additional beneficial effect on the degree of
supragingival plaque while both rinses were comparable
in the reduction of gingival inflammation when used
as adjunct to subjects’ oral hygiene procedures [31]. In





Discontinued intervention n= 3
Lost to follow up n= 17
(antibiotic usage, mucosal ulseration, 
irregular mouthrinse usage)
Discontinued intervention n= 3
Lost to follow up n= 14
(antibiotic usage, mucosal ulseration, 
irregular mouthrinse usage)
Allocated to CHX n = 45
Received allocated intervention n = 45
Allocated to placebo n = 42
Received allocated intervention n = 42
Randomized n = 87
Excluded n = 128
Not meeting inclusion criteria n = 92
Refused to participate n = 36
Assessed for eligibility n = 215
Figure 1 Flow chart of participation in the study.
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Table 1 Demographic data of the study groups
Parameters CHX group Placebo group
N 25 25
Age (years)




PBI≥ 2 at 8–13 sites 11 12
PBI≥ 2 at more than 13 sites 14 13
CHX: Chlorhexidine.
PBI: Papillary bleeding index.
SD: standard deviation.
Table 3 Clinical periodontal parameters of posterior
sampling sites in CHX and placebo groups
Parameters CHX group Placebo group
Baseline 4th week Baseline 4th week
PPD (mm) 3 (2–5) 3 (1–5) 3 (2–5) 3 (2–5)
PBI 2 (2–3) 1 (0–3) 2 (2–3) 1 (0–3)
PI 4 (2–5) 2 (0–4)* 4 (2–5) 3 (1–4)
CI 2 (0–2) 2 (0–2) 2 (0–2) 2 (0–2)
GCF (μl) 0.27 ± 0.15 0.17 ± 0.15 0.32 ± 0.22 0.20 ± 0.13
Data are given as mean ± SD or median (min-max).
*Significant difference from placebo at 4 weeks (p < 0.05).
CHX: Chlorhexidine.
PPD: Probing Pocket Depth, PBI: Papillary Bleeding Index, PI: Plaque Index,
CI: Calculus Index, GCF: Gingical Crevicular Fluid.
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4 weeks compared to baseline except for the PI of pos-
terior sampling sites. Posterior sampling sites of CHX
group had significantly lower PI values compared to
those sites of placebo group at four weeks. In our previ-
ous study PI scores of whole mouth and sampling sites
were found to be lower in CHX group than those of pla-
cebo at 4 weeks [31]. Taken together with the results of
the previous study we can conclude that both rinses are
comparable in the reduction of gingival inflammation
when used as adjunct to oral hygiene procedures, but
CHX mouthrinse have an additional beneficial effect
on the degree of supragingival plaque. The results by
Brownstein et al. showed that CHX mouthrinse in
addition to daily plaque control without initial prophy-
laxis reduced plaque significantly, but gingival index
scores remained unchanged after 2 months in patients
with moderate to severe gingivitis [46]. However, Corbet
observed no significant differences in plaque index
scores in patients with gingivitis while significant dif-
ference was found between CHX and control groups in
gingival bleeding scores after 3 months [5]. In other
study Zanatta et al. reported little antiplaque andTable 2 Clinical periodontal parameters of anterior
sampling sites in CHX and placebo groups
Parameters CHX group Placebo group
Baseline 4th week Baseline 4th week
PPD (mm) 3 (1–4) 2 (1–3) 3 (2–5) 3 (1–4)
PBI 2 (2–3) 1 (0–3) 2 (2–3) 1 (0–3)
PI 4 (1–5) 2 (0–4) 4 (2–5) 3 (1–5)
CI 1 (0–2) 2 (0–2) 0 (0–2) 2 (0–2)
GCF (μl) 0.19 ± 0.08 0.18 ± 0.2 0.20 ± 0.12 0.17 ± 0.1
Data are given as mean ± SD or median (min-max).
CHX: Chlorhexidine.
PPD: Probing Pocket Depth, PBI: Papillary Bleeding Index, PI: Plaque Index,
CI: Calculus Index, GCF: Gingical Crevicular Fluid.antigingivitis effect of CHX mouthrinse on previously
plaque covered surfaces and pointed out to the im-
portance of removing established biofilm before CHX
usage [47]. Lower PI scores at the posterior sites in CHX
group in the present study could reflect the adjunctive
benefit of CHX at sites where mechanical plaque control
is more difficult than the anterior sites. On the other
hand, the present study failed to show significant differ-
ences between test and control mouthrinses in the re-
duction of gingival inflammation after four weeks. In
other words, CHX, despite/although exerting ability to
inhibit MMPs and their oxidative activation as well as to
prevent oxidative inactivation of TIMP-1 and also α1-
antitrypsin [9,36-38] was not effective in decreasing gin-
gival inflammation to a statistically significantly greater
extent than the placebo, which might be due to the short
observation period of our study.
Pathogens in microbial dental plaque are capable of
stimulating host cells to recruit into periodontal tissues
[9]. As inflammatory cells such as polymorphonuclear
neutrophils, which play an important role in the devel-
opment of inflammatory injury, infiltrate the periodontal
tissues. They begin to release their MMPs, which are
considered among the indirect mechanisms of tissue de-
struction [9]. Hernandez et al. showed that GCF MMP-8
levels were related to progression episodes and treat-
ment responses in patients with chronic periodontitis
[19]. Researchers measured the GCF MMP-8 levels in
chronic periodontitis patients both active and inactive
sites before and after periodontal treatment, and they
found decreased GCF MMP-8 levels after periodontal
treatment except the active sites [19]. It was demon-
strated that CHX chip application following SRP was
beneficial in improving periodontal parameters and re-
ducing GCF MMP-8 levels for 6 months' duration [48].
To the best of our knowledge, this is the first study
evaluating the effect of the CHX mouthrinse on reso-
lution of gingival inflammation in gingivitis patients by
Figure 2 Distributions of the total amount of GCF MMP-8 in anterior (A) and posterior (B) sampling sites in the study groups. Box plots
show medians, 25th and 75th percentiles as boxes, 10th and 90th percentiles as whiskers. Outside values are shown as solid circles.
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and TIMP-1 levels. In the present study, GCF MMP-8
levels were not different at 4 weeks than those of base-
line in the study groups. Patients enrolled into the pre-
sent study were given oral hygiene instructions except
interdental cleaning, and they did not receive scaling
for their teeth. Therefore all patients in the present
study had interdental plaque to some extent even af-
ter 4 weeks. Furthermore supra and/or subgingival cal-
culus in addition to interdental plaque was also found in
some of the sampling sites. No reduction in GCF MMP-
8 levels at 4 weeks in gingivitis patients might be ex-
plained by the fact that the presence of interdental
plaque on interproximal surfaces and supra and/or
subgingival calculus prevent to complete resolution of
inflammation.
MMP activity can be regulated by several mechanisms
such as proteolytic degradation and inactivation, by non-
specific endogenous inhibitors, and especially by TIMPs
[9]. In the present study, GCF TIMP-1 levels of anterior
and posterior sites at four weeks were higher compared
to baseline in both CHX and placebo groups. Howeverno significant difference was found in GCF TIMP-1
levels of anterior and posterior sites at 4 weeks between
the study groups. It might be stated that daily plaque
control resulted in the increase of TIMP-1 levels in
GCF, but CHX mouthrinse could not cause an additional
increase in TIMP-1 at 4 weeks. It is well known that the
CHX digluconate is the most effective antimicrobial
agent against to bacteria, fungi and viruses in oral cavity.
Its antiplaque effect contributes to the supragingival
plaque control and antigingivitis feature had an add-
itional beneficial effect on both the degree of inflamma-
tion and the microbial accumulation within the oral
cavity [32-34,36-38]. However, it is also accepted that
mouthrinses have no place in the treatment of estab-
lished gingivitis or periodontitis and should only be used
after supra and subgingival scaling has been carried out
[47]. In the present study, the participants did not use
interdental cleaning devices and did not receive scaling
before the completion of the trial, and it might be stated
that CHX mouthrinse could not produce an additional
effects on GCF MMP-8 and TIMP levels because of the
presence of interdental plaque.
Figure 3 Distributions of the total amount of GCF -TIMP-1 in anterior (A) and posterior (B) sampling sites in the study groups. *significantly
different from baseline (p < 0.05). Box plots show medians, 25th and 75th percentiles as boxes, 10th and 90th percentiles as whiskers. Outside values
are shown as solid circles.
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present study. Because of females have hormonal chan-
ges, including the female patients might be consider as a
limitation of the study. A drop-out rate of this clinical
trial was very high. We think that this high rate of drop-
outs is caused by relatively long period of mouthrinse
usage, which makes the patients’ compliance difficult.
Besides antibiotic usage is also very common in Turkey,
and this is another reason for high drop-out rate. Add-
itionally, the changes of the GCF MMP-8 and TIMP-1
levels were evaluated at 4 weeks. However, the studies
analyzing the changes of these parameters in multiple
time points during long term would be useful for better
understanding the adjunctive effects of CHX mouthrinse
on clinical and serological parameters.
Conclusion
CHX mouthrinse as adjuncts to daily plaque control
could be effective in reduction of plaque accumulation
especially in posterior sites where mechanical plaquecontrol is more difficult than the anterior sites. CHX
usage had no significant effects on the GCF MMP-8 and
TIMP-1 levels in plaque-associated gingivitis. However,
daily plaque control procedures could be useful in the
increase of TIMP-1 levels in GCF regardless of the use
of CHX.
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